Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Ma, Wen jun ^a,b   Wang, Hai yong ^a   Teng, Li song ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Hangzhou Xixi Hospital   (China)

Author keywords

Alpha fetoprotein; Differentiation degree; Hepatectomy; Hepatocellular carcinoma; Prognosis

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PREDICTIVE VALUE; PREOPERATIVE PERIOD; RECURRENCE RISK; RISK FACTOR; SURVIVAL RATE;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREOPERATIVE PERIOD; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84883701868     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-212     Document Type: Article

References (24)

1. Gao JD, Shao YF, Xu Y, Ming LH, Wu ZY, Liu GT, Wang XH, Gao WH, Sun YT, Feng XL, Liang LM, Zhang YH, Sun ZT. Tight association of hepatocellular carcinoma with HBV infection in North China. Hepatobiliary Pancreat Dis Int 2005, 4:46-49.
2. Johnson PJ. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J Gastroenterol Hepatol 1999, 14:32-36. 10.1046/j.1440-1746.1999.01814.x, 10029275.
3. Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2008, 2:17-30. 10.1007/s12072-007-9038-x, 2716871, 19669276.
4. Snowberger N, Chinnakotla S, Lepe RM, Peattie J, Goldstein R, Klintmalm GB, Davis GL. Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther 2007, 26:1187-1194. 10.1111/j.1365-2036.2007.03498.x, 17944733.
5. Baig JA, Alam JM, Mahmood SR, Baig M, Shaheen R, Sultana I, Waheed A. Hepatocellular carcinoma (HCC) and diagnostic significance of A-fetoprotein (AFP). J Ayub Med Coll Abbottabad 2009, 21:72-75.
6. Lee HY, Jung JH, Kang YS, Kim YS, Moon HS, Park KO, Lee YS, Kim SM, Seo SW, Lee SW, Kim SH, Lee BS, Kim NJ. Clinical significance of transiently elevated serum AFP level in developing hepatocellular carcinoma in HBsAg positive-liver cirrhosis [Article in Korean]. Korean J Gastroenterol 2004, 43:252-259.
7. Chang SK, Hlaing WW, Yu RQ, Lee TW, Ganpathi IS, Madhavan KK. Value of alpha-foetoprotein for screening of recurrence in hepatocellular carcinoma post resection. Singapore Med J 2012, 53:32-35.
8. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000, 31:302-308. 10.1097/00004836-200012000-00007, 11129271.
9. Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 2002, 8:193-199.
10. Tong MJ, Hsien C, Song JJ, Kao JH, Sun HE, Hsu L, Han SH, Durazo FA, Saab S, Blatt LM. Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. Dig Dis Sci 2009, 54:1337-1346. 10.1007/s10620-009-0747-y, 19242792.
11. Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, Lam KC, Chan AT, Mok TS, Yeo W. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009, 27:446-452.
12. Li P, Wang SS, Liu H, Li N, McNutt MA, Li G, Ding HG. Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma. World J Gastroenterol 2011, 17:4563-4571. 10.3748/wjg.v17.i41.4563, 3226982, 22147961.
13. Zheng M, Ruan Y, Yang M, Guan Y, Wu Z. The comparative study on ultrastructure and immunohistochemistry in AFP negative and positive hepatocellular carcinoma. J Huazhong Univ Sci Technolog Med Sci 2004, 24:547-559. 10.1007/BF02911350, 15791836.
14. Fan WZ, Yang JY, Lü MD. Transcatheter arterial chemoembolization plus percutaneous thermal ablation in large hepatocellular carcinoma: clinical observation of efficacy and predictors of prognostic factors [Article in Chinese]. Zhonghua Yi Xue Za Zhi 2011, 91:2190-2194.
15. Luo JT, Wei X, Zhou HY, Li Q. Influencing factors for intrahepatic distant recurrence of liver cancer after radiofrequency ablation [Article in Chinese]. Zhonghua Wai Ke Za Zhi 2009, 47:1529-1531.
16. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma Y, Okita K, Omata M, Takayasu K, Yamaoka Y. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004, 15:796-802.
17. Reichman TW, Bahramipour P, Barone A, Koneru B, Fisher A, Contractor D, Wilson D, Dela Torre A, Cho KC, Samanta A, Harrison LE. Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma. J Gastrointest Surg 2005, 9:638-645. 10.1016/j.gassur.2004.11.002, 15862257.
18. Ha NB, Ha NB, Ahmed A, Ayoub W, Daugherty TJ, Chang ET, Lutchman GA, Garcia G, Cooper AD, Keeffe EB, Nguyen MH. Risk factors for hepatocellular carcinoma in patients with chronic liver disease: a case-control study. Cancer Causes Control 2012, 23:455-462. 10.1007/s10552-012-9895-z, 22258434.
19. Levi DM, Tzakis AG, Martin P, Nishida S, Island E, Moon J, Selvaggi G, Tekin A, Madrazo BL, Narayanan G, Garcia MT, Feun LG, Tryphonopoulos P, Skartsis N, Livingstone AS. Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era. J Am Coll Surg 2010, 210:727-734. 735-736, 10.1016/j.jamcollsurg.2010.01.007, 20421039.
20. Kobayashi M, Hosaka T, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y, Kumada H. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res 2011, 41:1036-1045. 10.1111/j.1872-034X.2011.00858.x, 21883741.
21. Jiang J, Wu C, Shen Y, Xu B, Zheng X, Li X, Xu N. Clinical application of determining serum AFP-IgM complexes for diagnosis of small hepatocellular carcinoma. Anticancer Res 2011, 31:687-691.
22. Xu WF, Fei YM, Zhou JK, Shen HJ, Chen XF, Lv QQ, Ding YY. Significance of serum golgi protein 73 (GP73), alpha-fetoprotein (AFP) and lectin-reactive alpha-fetoprotein (AFP-L3) expresssion in primary hepatic carcinoma [Article in Chinese]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2011, 25:286-288.
23. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007, 3:79-87.
24. Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. Gastroenterol 2010, 45:1272-1282.